Company news

Editas Medicine, Inc. news in 2026

Editas Medicine, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

October 14, 2026

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

October 8, 2026

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

September 8, 2026

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

August 5, 2026

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.

August 4, 2026

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

May 28, 2026

Editas Medicine Announces Proposed Public Offering

May 26, 2026

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

May 26, 2026

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

May 13, 2026

Editas Medicine Announces First Quarter 2026 Results and Business Updates

May 5, 2026

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

April 26, 2026

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

March 26, 2026

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

March 8, 2026

Decks in 2026